Sol-Gel to Present at Upcoming Healthcare Investor Conferences

NESS ZIONA, Israel, May 27, 2020 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced the Company will present at the following upcoming investor conferences.
Jefferies Virtual Healthcare Conference
Raymond James Human Health Innovation Conference
Sol-Gel’s senior management team will provide an overview of the Company and give a business update. Live webcasts of the presentations will be available under the “Events and Presentations” in the investors section of the Company’s website at www.sol-gel.com. An archived webcast recording of the events will be available on the website for approximately 30 days post presentation.About Sol-Gel TechnologiesSol-Gel is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Sol-Gel leverages its proprietary microencapsulation technology platform for Twyneo, for the treatment of acne vulgaris, and Epsolay, for the treatment of papulopustular rosacea. The Company’s pipeline also includes SGT-210, an early-stage topical epidermal growth factor receptor inhibitor, erlotinib, for the treatment of punctate palmoplantar keratoderma, and preclinical assets tapinarof and roflumilast. For additional information, please visit www.sol-gel.com.For further information, please contact:
Sol-Gel Contact:
Gilad Mamlok
Chief Financial Officer
+972-8-9313433
Investor Contact:
Lee M. Stern
Solebury Trout
[email protected]
Source: Sol-Gel Technologies Ltd. 


Bay Street News

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search